Researchers from Warwick Medical School have discovered a critical point of failure in the microscopic transport system that operates inside every cell in the human body.
The study, published today in Nature Communications, explains how this tiny ‘railway’ system is a key target for cancer drugs and, as such, how this new discovery reveals how better drugs might be made. The tracks of this so called ‘railway’ are tiny tubes, called microtubules, 1000 times thinner than a human hair.
The research shows that a narrow seam that runs along the length of the microtubules is the weakest point. If the seam cracks and splits, the microtubule dissolves.
It has been known for some time that microtubules have a single seam that zips the structure together along its length, but the function of this seam has evaded scientists until now. By building microtubules with extra seams in the laboratory, and examining their stability using video microscopes, the researchers found that the more seams the microtubule has, the more unstable it becomes.
The new work dramatically alters thinking on how the microtubule system works and the search is now on for factors inside the cell that influence the stability of microtubule seams.
Microtubules are a validated target for cancer therapy drugs. For example Taxol™, used in breast cancer therapy, binds to microtubules and stops the microtubule from dissolving. This means the microtubule tracks cannot remodel themselves prior to cell division, which in turn stops the cells dividing, thus arresting the growth of cells including those forming cancerous tumours.
Professor Robert Cross, head of the research team at Warwick Medical School, explained, “It is clear that any new drugs aiming to stabilize or destabilize microtubules must target the microtubule seam. We expect this to lead us to a better understanding of the way microtubules are regulated in cells and why this sometimes goes wrong, such as in development of cancer.”
“Our findings help us to understand how some existing cancer treatment drugs actually work and this in turn should lead to development of new generations of better and more effective anti-microtubule drugs.”
The research was funded by the Association for International Cancer Research (AICR) and Marie Curie Cancer Care.
For further information, a copy of the full paper, or to arrange interviews with Professor Cross, contact Luke Harrison, Press Officer, on +44 (0) 2476 574255/150483 or +44 (0) 7920531221, or by email on firstname.lastname@example.org